{"title":"Design of experiments to optimize gallic acid carbon-based nanoparticle synthesis for enhanced photodynamic therapy in cancer cells.","authors":"Koranat Dechsri, Supusson Pengnam, Thapakorn Charoenying, Boonnada Pamornpathomkul, Chaiyakarn Pornpitchanarong, Prasopchai Patrojanasophon, Tanasait Ngawhirunpat, Theerasak Rojanarata, Praneet Opanasopit","doi":"10.1080/10837450.2025.2597342","DOIUrl":null,"url":null,"abstract":"<p><p>Carbon-based nanoparticles (CNPs) have attracted significant attention as photosensitizers for photodynamic therapy (PDT) due to their biocompatibility, facile synthesis, and ability to generate reactive oxygen species (ROS). In this study, green-synthesized gallic acid CNPs (GACNPs) were optimized and characterized for their physicochemical properties and biomedical potential. GACNPs exhibited no cytotoxicity to normal cells at concentrations up to 250 µg/mL, demonstrating excellent biocompatibility. Under LED light irradiation (350-700 nm, 0.124 W/cm<sup>2</sup>, 10 min), GACNPs efficiently generated ROS, as assessed by photodynamic activity and intracellular ROS detection, confirming their photosensitizing function. The anticancer efficacy of GACNPs was evaluated in HeLa and MDA-MB-231 cell lines, revealing IC<sub>50</sub> values of 2.92 ± 0.14 µg/mL (exposure) versus 3.74 ± 0.22 µg/mL (non-exposure) for HeLa and 2.62 ± 0.24 µg/mL (exposure) versus 4.14 ± 0.19 µg/mL (non-exposure) for MDA-MB-231 cells, indicating significantly enhanced cytotoxicity upon light exposure. Furthermore, both cell lines showed that GACNPs significantly enhanced the anticancer effect upon exposure compared to the GA solution. Apoptosis assays showed 64% cell death after exposure, compared to 47% without exposure, in HeLa cells, and 93% cell death after exposure, compared to 74% in MDA-MB-231 cells. These findings demonstrate that GACNPs are promising nano-photosensitizers for PDT-based cancer therapy, combining low cytotoxicity with high ROS-mediated anticancer efficacy.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"48-67"},"PeriodicalIF":2.9000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Development and Technology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10837450.2025.2597342","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Carbon-based nanoparticles (CNPs) have attracted significant attention as photosensitizers for photodynamic therapy (PDT) due to their biocompatibility, facile synthesis, and ability to generate reactive oxygen species (ROS). In this study, green-synthesized gallic acid CNPs (GACNPs) were optimized and characterized for their physicochemical properties and biomedical potential. GACNPs exhibited no cytotoxicity to normal cells at concentrations up to 250 µg/mL, demonstrating excellent biocompatibility. Under LED light irradiation (350-700 nm, 0.124 W/cm2, 10 min), GACNPs efficiently generated ROS, as assessed by photodynamic activity and intracellular ROS detection, confirming their photosensitizing function. The anticancer efficacy of GACNPs was evaluated in HeLa and MDA-MB-231 cell lines, revealing IC50 values of 2.92 ± 0.14 µg/mL (exposure) versus 3.74 ± 0.22 µg/mL (non-exposure) for HeLa and 2.62 ± 0.24 µg/mL (exposure) versus 4.14 ± 0.19 µg/mL (non-exposure) for MDA-MB-231 cells, indicating significantly enhanced cytotoxicity upon light exposure. Furthermore, both cell lines showed that GACNPs significantly enhanced the anticancer effect upon exposure compared to the GA solution. Apoptosis assays showed 64% cell death after exposure, compared to 47% without exposure, in HeLa cells, and 93% cell death after exposure, compared to 74% in MDA-MB-231 cells. These findings demonstrate that GACNPs are promising nano-photosensitizers for PDT-based cancer therapy, combining low cytotoxicity with high ROS-mediated anticancer efficacy.
期刊介绍:
Pharmaceutical Development & Technology publishes research on the design, development, manufacture, and evaluation of conventional and novel drug delivery systems, emphasizing practical solutions and applications to theoretical and research-based problems. The journal aims to publish significant, innovative and original research to advance the frontiers of pharmaceutical development and technology.
Through original articles, reviews (where prior discussion with the EIC is encouraged), short reports, book reviews and technical notes, Pharmaceutical Development & Technology covers aspects such as:
-Preformulation and pharmaceutical formulation studies
-Pharmaceutical materials selection and characterization
-Pharmaceutical process development, engineering, scale-up and industrialisation, and process validation
-QbD in the form a risk assessment and DoE driven approaches
-Design of dosage forms and drug delivery systems
-Emerging pharmaceutical formulation and drug delivery technologies with a focus on personalised therapies
-Drug delivery systems research and quality improvement
-Pharmaceutical regulatory affairs
This journal will not consider for publication manuscripts focusing purely on clinical evaluations, botanicals, or animal models.